People with von Willebrand disease (VWD) are at increased risk of bleeding, which may manifest as frequent nosebleeds, easy bruising, prolonged bleeding from minor cuts, excessive bleeding during dental treatment, and heavy menstrual bleeding.1
Prophylaxis with a von Willebrand factor (VWF) concentrate is recommended to prevent bleeding in people with severe von Willebrand disease.2, 3 wilate® prophylaxis is effective in adults, adolescents and children with all von Willebrand disease types, reducing the rate of bleeding compared with on-demand treatment.4
Prophylaxis with VWF concentrates*
* Prevention and treatment of haemorrhage or surgical bleeding in von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or contra-indicated.
Can effectively
prevent bleeding2
May reduce the burden of von Willebrand disease and improve quality of life2
Is recommended in patients with severe von Willebrand disease4
A significant proportion of people with von Willebrand disease may be undertreated2
of patients with severe von Willebrand disease receive prophylaxis with VWF concentrates5
wilate® is indicated for prophylactic use in von Willebrand disease in the European Union5
Efficacy of wilate® prophylaxis has been demonstrated in
Prospective clinical trials in adults4 and children4,6
Data from 4 prospective, multicentre Phase II/III trials
Data from 4 prospective, multicentre Phase II/III trials
of patients had
type 3 VWD
median (range 3-46 months) duration of prophylaxis
Data from 4 prospective, multicentre Phase II/III trials
Bleeding frequency significantly reduced after the start of wilate® prophylaxis